XOOMAR
Get a free API key

ADARx Pharmaceuticals (ADRX)

ADARx Pharmaceuticals on one page: daily short volume, large holders and insider trades. Listed on Nasdaq.

Download CSV

85.2%

Short share of volume

2026-10-08

$87.7M

Insider flow, 90 days

13 buys, 0 sells

As of 2026-10-08.

Daily short volume

FINRA Reg SHO, the last 10 sessions. JSON

As of 8 October 2026, the short share of ADRX volume is 85.2%, up 15.5 points over the last five sessions. Over the last 10 readings it ranged from 28.0% (25 September 2026) to 85.2% (7 October 2026). The latest reading sits at the top of that range. The latest reading is 28.5 points above the 10-session average of 56.7%, on 211K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-10-08180K211K85.2%0
2026-10-07318K373K85.2%0
2026-10-06385K584K65.9%46,241
2026-10-05231K519K44.5%0
2026-10-02199K324K61.4%0
2026-10-01299K429K69.8%0
2026-09-30170K313K54.4%0
2026-09-29121K270K44.8%0
2026-09-28169K602K28.1%0
2026-09-25428K1.5M28.0%175

Insider trades

SEC Form 4, newest first, 50 of 51 shown. JSON

Insiders at ADRX reported 13 open-market buys worth $87.7M in the last 90 days and no open-market sells. Latest filing: LAV Biosciences Fund V, L.P. (10% owner) on 2026-09-28.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-09-28LAV Biosciences Fund V, L.P.10% ownerConversion308Kprice not stated in the filingnot stated308K
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC10% ownerBuy593K$17.00$10.1M593K
2026-09-28George SimeonDirector, 10% ownerBuy593K$17.00$10.1M593K
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerBuy588K$17.00$10.0M588K
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerBuy62K$17.00$1.0M9.3M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerConversion256Kprice not stated in the filingnot stated9.2M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerConversion513Kprice not stated in the filingnot stated9.0M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerConversion1.3Mprice not stated in the filingnot stated8.5M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerConversion7.1Mprice not stated in the filingnot stated7.1M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerBuy300K$17.00$5.1M14.3M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerConversion564Kprice not stated in the filingnot stated14.0M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerConversion770Kprice not stated in the filingnot stated13.5M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerConversion2.0Mprice not stated in the filingnot stated12.7M
2026-09-28ORBIMED ADVISORS LLCDirector, 10% ownerConversion10.7Mprice not stated in the filingnot stated10.7M
2026-09-28GORDON CARL LDirector, 10% ownerBuy588K$17.00$10.0M588K
2026-09-28GORDON CARL LDirector, 10% ownerBuy62K$17.00$1.0M9.3M
2026-09-28GORDON CARL LDirector, 10% ownerConversion256Kprice not stated in the filingnot stated9.2M
2026-09-28GORDON CARL LDirector, 10% ownerConversion513Kprice not stated in the filingnot stated9.0M
2026-09-28GORDON CARL LDirector, 10% ownerConversion1.3Mprice not stated in the filingnot stated8.5M
2026-09-28GORDON CARL LDirector, 10% ownerConversion7.1Mprice not stated in the filingnot stated7.1M
2026-09-28GORDON CARL LDirector, 10% ownerBuy300K$17.00$5.1M14.3M
2026-09-28GORDON CARL LDirector, 10% ownerConversion564Kprice not stated in the filingnot stated14.0M
2026-09-28GORDON CARL LDirector, 10% ownerConversion770Kprice not stated in the filingnot stated13.5M
2026-09-28GORDON CARL LDirector, 10% ownerConversion2.0Mprice not stated in the filingnot stated12.7M
2026-09-28GORDON CARL LDirector, 10% ownerConversion10.7Mprice not stated in the filingnot stated10.7M
2026-09-28Chimovits ErezDirectorBuy62K$17.00$1.0M9.3M
2026-09-28Chimovits ErezDirectorConversion256Kprice not stated in the filingnot stated9.2M
2026-09-28Chimovits ErezDirectorConversion513Kprice not stated in the filingnot stated9.0M
2026-09-28Chimovits ErezDirectorConversion1.3Mprice not stated in the filingnot stated8.5M
2026-09-28Chimovits ErezDirectorConversion7.1Mprice not stated in the filingnot stated7.1M
2026-09-28LAV Biosciences Fund V, L.P.10% ownerConversion308Kprice not stated in the filingnot stated308K
2026-09-28LAV Biosciences Fund V, L.P.10% ownerConversion154Kprice not stated in the filingnot stated11.2M
2026-09-28LAV Biosciences Fund V, L.P.10% ownerConversion513Kprice not stated in the filingnot stated11.1M
2026-09-28LAV Biosciences Fund V, L.P.10% ownerConversion1.7Mprice not stated in the filingnot stated10.6M
2026-09-28LAV Biosciences Fund V, L.P.10% ownerConversion8.9Mprice not stated in the filingnot stated8.9M
2026-09-28George SimeonDirector, 10% ownerConversion169Kprice not stated in the filingnot stated1.8M
2026-09-28George SimeonDirector, 10% ownerConversion1.7Mprice not stated in the filingnot stated1.7M
2026-09-28George SimeonDirector, 10% ownerBuy415K$17.00$7.1M2.0M
2026-09-28George SimeonDirector, 10% ownerConversion1.5Mprice not stated in the filingnot stated1.5M
2026-09-28George SimeonDirector, 10% ownerBuy593K$17.00$10.1M5.6M
2026-09-28George SimeonDirector, 10% ownerConversion513Kprice not stated in the filingnot stated5.0M
2026-09-28George SimeonDirector, 10% ownerConversion1.1Mprice not stated in the filingnot stated4.4M
2026-09-28George SimeonDirector, 10% ownerConversion3.3Mprice not stated in the filingnot stated3.3M
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC10% ownerConversion169Kprice not stated in the filingnot stated1.8M
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC10% ownerConversion1.7Mprice not stated in the filingnot stated1.7M
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC10% ownerBuy415K$17.00$7.1M2.0M
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC10% ownerConversion1.5Mprice not stated in the filingnot stated1.5M
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC10% ownerBuy593K$17.00$10.1M5.6M
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC10% ownerConversion513Kprice not stated in the filingnot stated5.0M
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC10% ownerConversion1.1Mprice not stated in the filingnot stated4.4M

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

9 holders report 5% or more of ADRX in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is ORBIMED ADVISORS LLC at 14.0% of the class (14,913,764 shares), filed 2026-10-02 for an event on 2026-09-28.

FiledFormHolderSharesOf classEvent
2026-10-0513DSimeon Georgeindividual9.9M9.3%2026-09-28
2026-10-0513DSR One Capital Management, LLCother entity9.9M9.3%2026-09-28
2026-10-0513DSR One Capital Fund I Aggregator, LPpartnership5.6M5.2%2026-09-28
2026-10-0513DSR One Capital Partners I, LPpartnership5.6M5.2%2026-09-28
2026-10-0513DSR One Capital Opportunities Partners I, LPpartnership2.0M1.8%2026-09-28
2026-10-0513DSR One Capital Opportunities Fund I, LPpartnership2.0M1.8%2026-09-28
2026-10-0513DSR One Co-Invest III, LLCother entity1.8M1.7%2026-09-28
2026-10-0513DSR One Co-Invest III Manager, LLCother entity1.8M1.7%2026-09-28
2026-10-0513DSR One Capital SMA Partners, LPpartnership593K0.6%2026-09-28
2026-10-0513DAMZL, LPpartnership593K0.6%2026-09-28
2026-10-0213DORBIMED ADVISORS LLCinvestment adviser14.9M14.0%2026-09-28
2026-10-0213DORBIMED CAPITAL GP VII LLCother entity14.3M13.4%2026-09-28
2026-10-0213DORBIMED ADVISORS ISRAEL II LTDcorporation9.3M8.7%2026-09-28
2026-10-0213DORBIMED ISRAEL GP II, L.P.partnership9.3M8.7%2026-09-28
2026-10-0213DOrbiMed Genesis GP LLCother entity588K0.6%2026-09-28
2026-10-0113GBCLS Fund III Investments, LPpartnership6.7M6.3%2026-09-24

What this page is

ADARx Pharmaceuticals in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows ADARx Pharmaceuticals (ADRX), SEC CIK 1802369, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Daily short volume
FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-08.JSON and CSV
Large holders
SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-05.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-28.JSON and CSV
Company record
EDGAR filing index for CIK 1802369Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other company pages

Datasets

Frequently Asked Questions

How much of ADRX is sold short?
FINRA has not reported a short position for ADRX at the latest settlement.
What is ADRX's daily short volume?
On 2026-10-08, 179,781 of the 210,971 ADRX shares reported to FINRA were sold short, 85.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ADRX have fails to deliver?
ADRX does not appear in the SEC fails-to-deliver files on record.
Are ADRX insiders buying or selling?
Insiders at ADRX reported 13 open-market buys worth $87.7M in the last 90 days and no open-market sells. Latest filing: LAV Biosciences Fund V, L.P. (10% owner) on 2026-09-28.
Who owns 5% or more of ADRX?
9 holders report 5% or more of ADRX in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is ORBIMED ADVISORS LLC at 14.0% of the class (14,913,764 shares), filed 2026-10-02 for an event on 2026-09-28.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.